Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options,
After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left scrambling to figure out what to do.
This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
Pfizer PFE said it is withdrawing its sickle-cell drug (“SCD”) drug, Oxbryta from worldwide markets. Merck’s MRK Keytruda ...
Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...
The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...
European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback